Overview
Muller & Phipps distributes pharmaceutical and healthcare products through a nationwide network, including a newer therapeutic-nutrition offering. The September quarter restored an operating profit, but finance costs and other below-operating items left the group loss-making and further reduced the owners' equity deficit.
Price performance
The share closed at LKR 3.80 on 6 November 2026, after gaining 72.7% over three months while the ASPI fell 0.6%. It was at its 52-week high, so the recent move has taken the price to the top of its own annual range rather than merely recovering part of an earlier decline.
Trading activity has risen above its own recent norm, but liquidity remains limited: median daily turnover was LKR 739,388, and a LKR 1 million order is more than everything that trades on a typical day (135% of it). The record since November 2023 includes seven falls of 15% or more, with the deepest 32%, showing that large retreats have occurred despite the current high.
Valuation
Conventional valuation multiples are unavailable because trailing earnings are negative and book value attributable to owners is negative. That means neither P/E nor P/B can describe what the market is paying for in the usual terms, while no dividend is on record in the last two years.
The market-wide valuation measure places MULL in the Overvalued band, scoring 1 of 100 on price against filed earnings, book value and dividends. The company's own historical P/E and P/B comparisons are also unavailable, so the available valuation evidence offers no earnings, asset-value or income support for the LKR 1.1 billion voting-line market value.
News and sentiment
Direct coverage is thin: the 90-day record contains two material articles, both neutral. Both were reported on 12 October 2026 and concern regulatory disclosures, including a share purchase disclosure; the supplied coverage gives no transaction terms or operating implication.
Financials
September revenue fell 10.5% year-on-year to LKR 132.1 million, but operating profit improved by LKR 4.1 million to LKR 3.4 million. The business therefore covered its direct operating costs in the quarter, unlike a year earlier, but this did not yet translate into profit available to shareholders.
Gross margin was 18.6% versus 20.7% a year earlier, operating margin was 2.5% versus -0.5%, and net margin was -2.3% versus -0.4%. The group still lost about 2 cents on each rupee of sales, and the September net margin was among its worst, ranking sixth out of seven comparable September quarters; gross margin carried the same rank. Operating margin was middling at fourth out of seven.
Below-operating charges were LKR 6.4 million, exceeding operating profit and turning it into a LKR 3.0 million net loss. That loss was LKR 2.4 million wider than the prior-year quarter. The latest audited year, ended March 2026, recorded a LKR 71.4 million net loss, following an LKR 83.7 million loss in the preceding year.
Risks
The central risk is the weak capital position. Equity attributable to owners was negative LKR 165.0 million at September 2026 while total debt was LKR 302.5 million, leaving lenders and creditors materially more important to the financing structure than ordinary shareholders' book capital.
Finance costs and other below-operating charges were LKR 6.4 million in the latest quarter, more than the LKR 3.4 million operating profit. In the year ended March 2026, interest cover was negative 2.96 times, meaning operating profit was insufficient to cover the interest bill.
As at 9 November 2026, the wider backdrop included October inflation of 8.3%, a 100-basis-point policy-rate increase and a 6.7% rupee depreciation through 6 November. As an importer and distributor with material debt, the company is exposed to a more difficult cost and financing environment, although the supplied data does not quantify its currency exposure.
Outlook
As at 9 November 2026, the next decisive event is the December 2026 interim filing, expected between 2 and 14 February 2027. It will show whether the September operating profit was sufficient to absorb finance costs and narrow the net loss, or whether the balance-sheet deficit continues to deepen.
The current data cannot establish whether the operating improvement is durable. It also cannot measure the profit contribution from the newer therapeutic-nutrition distribution activity.